The analysis showed that the expression of PLEKHA4 was upregulated in central nervous system neoplasms, breast cancer, head and neck cancer, and melanoma and downregulated in bladder cancer and ovarian cancer (Figure 1(a)). Here, PLEKHA4 is linked to breast cancer.